The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC.
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This study is a prospective, single-arm phase II clinical study to evaluate the effectiveness
of IBI318 combined with lenvatinib in subjects with advanced or metastatic non-small cell
lung cancer who failed first-line PD-1/PD-L1 And safety research. After being screened to
meet the inclusion criteria, they will receive IBI318 combined with lenvatinib until the
disease progresses, death, toxicity is intolerable, informed consent is withdrawn, new
anti-tumor therapy is started, or the treatment is terminated for other reasons specified in
the plan.